The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K
Danijela Maksimović‐Ivanić(Institute for Biological Research “Siniša Stanković”), Sanja Mijatović(University of Belgrade), Paolo Fagone(University of Catania), James A. McCubrey(East Carolina University), Djordje Miljković(University of Belgrade), Stanislava Stošić‐Grujičić(Institute for Biological Research “Siniša Stanković”), Marija Mojić(Northwell Health), Miloš Kuzmanović(University of Belgrade), Mirna Bulatović(University of Belgrade), Milica Radojković(University of Belgrade), Slobodan Ristić(University of Belgrade), Massimo Libra(University of Catania), Ferdinando Nicoletti(University of Catania), Eugenio Cavalli(Centro Neurolesi Bonino Pulejo)
Cited by 27
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
|Frontiers in Pharmacology|2018|878
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508